Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life sciences and biotech startups, today announced that Carmine Therapeutics and STIMIT are the winners of Bristol-Myers Squibb's 2019 Golden Tickets for LabCentral.
Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA(1). Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid tumors with KRAS mutations.
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
- Details
- Category: AstraZeneca
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in Europe and Russia.
OPKO and Pfizer announce positive Phase 3 top-line results for somatrogon
- Details
- Category: Pfizer
OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN® (somatropin) for injection, as measured by annual height velocity at 12 months.
Amgen recommends rejection of 'mini-tender' offer from TRC Capital Corporation
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadian investment company, to purchase up to 500,000 shares of Amgen's common stock beginning on Oct. 14, 2019.
Bayer launches LifeHub UK focused on artificial intelligence to optimize data-driven drug discovery and disease diagnosis
- Details
- Category: Bayer
Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The new hub is the seventh pillar of Bayer's global network of LifeHubs designed to accelerate the co-exploration and development of pioneering solutions to solve global challenges in health and nutrition.
Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts.
More Pharma News ...
- The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
- Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
- Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
- Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing
- Abbott and Omada Health partner to offer integrated digital health and coaching experience for people with Type 2 diabetes
- Bayer inks deals with eleven startups under G4A Digital Health Partnerships program
- Abbott and Abbott Fund launch 'Future Well Kids' program to help students shape healthier lives